Sustained API pricing pressure
API business continues to face pricing softness across key molecules, though the pace of decline has moderated.
AKUMSDRUGSPHARMACEUTICAL / Q3-FY26 / risks
Keep the risk register visible.
Akums Drugs & · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Potential delays in regulatory approvals for new facilities
The injectables facility is still ramping up with low utilization; delays in client audits or approvals could impact revenue contribution.
Trade generic segment losses may persist
Trade generic revenue declined 18% YoY and remains loss-making; management expects some bottom-line impact in Q4.
Dependence on CDMO volume growth sustainability
Analyst questioned whether the strong volume growth is sustainable; management cited market share gains but acknowledged it's market-driven.